CTOs on the Move

Accelerated Technologies Partners

www.atpfunds.com

 
Accelerated Technologies Partners is a Hackensack, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.atpfunds.com
  • 401 Hackensack Ave Fl 9
    Hackensack, NJ USA 07601
  • Phone: 646.367.5900

Executives

Name Title Contact Details

Similar Companies

Epitopix

Epitopix is a Willmar, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Elixirgen Therapeutics

A clinical-stage biotechnology company focused on the discovery, development, and commercialization of therapies for genetic diseases and vaccines

Bruker

Right from the beginning, which is now more than fifty years ago, Bruker has been driven by a single idea: to provide the best technological solution for each analytical task` Today, worldwide, more than 6,500 employees in over 90 locations on all continents are focusing their efforts on this permanent challenge` Bruker systems cover a broad spectrum of applications in all fields of research and development and are used in all industrial production processes for the purpose of ensuring quality and process reliability` Bruker continues to build upon its extensive range of products and solutions, expand its broad base of installed systems and maintain a strong reputation amongst its customers` As one of the world's leading analytical instrumentation companies, Bruker remains focused on developing state-of-the-art technologies and innovative solutions for today’s ever complex analytical questions` Bruker - Innovation with Integrity`

Applied Therapeutics

Applied Therapeutics is a clinical-stage biopharmaceutical company that uses our novel drug-development approach to create transformative, life-changing treatments for the patients who desperately need them.

TCR2

TCR² Therapeutics Inc. is a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for patients suffering from cancer. TCR²`s proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC-T cells) specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). In preclinical studies, TRuC-T cells have demonstrated superior anti-tumor activity compared to chimeric antigen receptor T cells (CAR-T cells), while exhibiting lower levels of cytokine release.